# Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland

> **NCT07526961** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 240 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **COMBINATION_PRODUCT:** Nivolumab + Ipilimumab + Chemotherapy

## Key facts

- **NCT ID:** NCT07526961
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-12-01
- **Primary completion:** 2026-01-20
- **Final completion:** 2026-01-20
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07526961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07526961, "Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07526961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*